Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... For example, in 2016 Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Highlights,Eli Lilly posts revenue growth supported by healthcare innovation.,Sector trends mirror broader momentum within the S&P 500.,Commercial focus remains aligned with index ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

Eli Lilly (NYSE: NYSE:LLY) is set to report its first-quarter earnings on Thursday, May 1st, before the market opens. Street ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts. Read more here.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...